Predictive factors of efficacy of Nalfurafine hydrochloride for pruritus in patients with PBC

Predictive factors of efficacy of Nalfurafine hydrochloride for pruritus in patients with PBC - Predictive factors of Nalfurafine treatment in PBC with pruritus

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021681

Enrollment

Registered

2016-04-11

Start date

2016-04-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary biliary cholangitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with PBC, who were indicated for nalfurafine treatment by physician.

Exclusion criteria

Exclusion criteria: Patients with pregnancy, patients with malignancy, patients with a history of allergy to nalfurafine, patients with severe liver impairment (Child-Pugh grade C), and patients who were not indicated for nalfurafine treatment.

Design outcomes

Primary

Measure	Time frame
Improvement of pruritus at 8 weeks after nalfurafine administration.	—

Secondary

Measure	Time frame
blood biochemistry, serum autaxin levels	—

Countries

Japan

Contacts

Public ContactKeisuke Kakisaka

Iwate Medical University Division of Hepatology, Department of Internal medicine

keikaki@iwate-med.ac.jp019-651-5111

Outcome results